US20100326915A2 - Hollow fiber capillary membrane and method for the production thereof - Google Patents
Hollow fiber capillary membrane and method for the production thereof Download PDFInfo
- Publication number
- US20100326915A2 US20100326915A2 US12/594,694 US59469408A US2010326915A2 US 20100326915 A2 US20100326915 A2 US 20100326915A2 US 59469408 A US59469408 A US 59469408A US 2010326915 A2 US2010326915 A2 US 2010326915A2
- Authority
- US
- United States
- Prior art keywords
- hollow fibre
- layer
- fibre membrane
- membrane according
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 18
- 239000012510 hollow fiber Substances 0.000 title abstract 2
- 210000001601 blood-air barrier Anatomy 0.000 title description 6
- 239000012528 membrane Substances 0.000 claims abstract description 115
- 239000000835 fiber Substances 0.000 claims description 69
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 37
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 37
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 37
- 238000009987 spinning Methods 0.000 claims description 32
- 239000011148 porous material Substances 0.000 claims description 28
- 229920002492 poly(sulfone) Polymers 0.000 claims description 19
- 238000001556 precipitation Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002033 PVDF binder Substances 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 239000004697 Polyetherimide Substances 0.000 claims description 4
- 239000004642 Polyimide Substances 0.000 claims description 4
- 238000001631 haemodialysis Methods 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920001601 polyetherimide Polymers 0.000 claims description 4
- 229920001721 polyimide Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000002615 hemofiltration Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 238000001728 nano-filtration Methods 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 210000000601 blood cell Anatomy 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- 230000035699 permeability Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000002616 plasmapheresis Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241001146209 Curio rowleyanus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229920003287 Udel® P-3500 LCD Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000045 pyrolysis gas chromatography Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
- B01D69/087—Details relating to the spinning process
- B01D69/088—Co-extrusion; Co-spinning
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/027—Nanofiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/12—Composite membranes; Ultra-thin membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/12—Composite membranes; Ultra-thin membranes
- B01D69/1212—Coextruded layers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/44—Polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups B01D71/26-B01D71/42
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/44—Polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups B01D71/26-B01D71/42
- B01D71/441—Polyvinylpyrrolidone
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/02—Details relating to pores or porosity of the membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/02—Details relating to pores or porosity of the membranes
- B01D2325/0283—Pore size
Definitions
- the present invention relates to a hollow fibre capillary membrane and a method for the production thereof plus its use in particular in plasmapheresis.
- Capillary membranes of different compositions are known in particular because of their increasing use in dialysis or also in plasmapheresis.
- the use and the production of membranes, in particular of capillary membranes, in dialysis is described for example in the publication by Samtleben and Lysaght in: Horl et al. Replacement of Renal Function by Dialysis 5th ed., Kluwer, 2004, pp. 709 to 724.
- WO 96/37282 describes a membrane, in particular for haemodialysis, which has a separating layer with a cut-off between 500 and 5000000 dalton, a supporting layer and a layer co-determining the hydraulic permeability, wherein the separation limit and hydraulic permeability are set mutually independently.
- it is very expensive to build up the membrane with different pore sizes within the individual layers.
- EP 1547628 A1 describes plasma purification membranes and a plasma purification system, and in particular is geared towards specific physical properties, in particular the breaking resistance of the membrane due to the high stress load during plasma purification. This involves in particular protein and immunoglobulin permeability.
- a gradient of the pore size is set, wherein a larger pore size is to be found on the outer surface than on the inner surface of the membrane.
- U.S. Pat. No. 6,565,782 relates to synthetic polymeric microfiltration membrane materials with high surface porosity which can be obtained by co-casting a sulfone polymer with a hydrophilic polymer, such as polyvinylpyrrolidone. Disadvantages occur with this membrane in particular in relation to the separation of cellular components of the blood from the plasma phase, since the pressure on the blood cells caused by the use of small-pored membranes can lead to damage to the blood cells.
- the hollow fibre membrane is produced by means of a hollow fibre spinneret
- the hollow fibre membrane is produced in a so-called precipitation spinning process, wherein the polymers to be precipitated emerge from an annular slit of a spinneret arrangement, while the corresponding precipitant flows out of a central precipitant bore.
- a hollow fibre spinneret of the named type is disclosed for example in DE A1.
- Typical plasmapheresis filters of the state of the art contain in most cases hydrophobic membranes, for example of polypropylene, polysulfone, etc.
- these hydrophobic membranes cannot be wetted with water, the filters containing these membranes are typically made hydrophilic with water under pressure. For the subsequent blood treatment, it is therefore ensured that all the air inclusions inside the pores have been expelled and therefore do not enter the blood circulation.
- these filter modules with hydrophobic hollow fibre membranes must be delivered filled with water to the clients and patients. Attempts are being made to circumvent the raw material and distribution costs and the difficulty of guaranteeing the sterility of such filled modules.
- a hollow fibre membrane which in particular makes possible a gentle plasmapheresis, in particular a gentle plasma filtration of blood. Furthermore, such a hollow fibre membrane should also have, in addition to the largest possible openings for a good lipoprotein permeability with a simultaneously high selectivity, a high porosity for an improved blood compatibility.
- this object is achieved by an integral hollow fibre membrane, consisting of two co-extruded layers A and B, wherein layer B has a non-woven type structure with a mesh size of 0.1 to 10 ⁇ m and layer A has a porous structure.
- mesh size is meant in this connection the greatest distance, in a non-woven type or net-like structure, between the individual branchings of the structure forming the non-woven material or net. The thickness of the webs of the branching is 0.1-0.5 ⁇ m in this case.
- Layer B preferably forms the so-called blood-contact side and layer A the filtrate side of the hollow fibre membrane, for example in a blood treatment in which the blood is passed through the inside of the hollow fibre.
- the blood-contact side is the inner layer of the hollow fibre membrane and layer A, thus the filtrate side, is the outer layer of the membrane.
- layer B it is also possible for layer B to be the outer layer (the blood-contact side) and layer A the inner layer (filtrate side).
- a lower negative pressure acts on a section of a blood cell through the transmembrane pressure difference than in the case of a small-pored membrane of the state of the art, with the result that in particular the cellular components of the blood can be separated particularly gently from the plasma phase of the blood.
- layer A consists of at least three successive zones A1, A2, A3 of different porosity, wherein zone A1 forms the surface of layer A and has pores with an average pore size of 0.7 to 2 ⁇ m.
- the thickness of zone A1 typically lies in the range of 9 to 11 ⁇ m, and is preferably 10 ⁇ m, with a preferred wall thickness of approx. 60 ⁇ m.
- zone A2 Adjoining this is zone A2 which is arranged between zones A1 and A3 and has an average pore size of more than 200 nm.
- This zone A2 is typically approx. 10 ⁇ m, with a preferred total wall thickness of 60 ⁇ m. In general, the thickness of zone A2 is thus approximately 1 ⁇ 6 of the total wall thickness.
- Zone A3 is directly adjacent to layer B and is typically positively connected to the non-woven type structure of layer B.
- Zone A3 has a pore-size gradient towards layer B, i.e. the pore size increases towards layer B.
- the thickness of zone A3 is approx. 30 ⁇ m for a total wall thickness of 60 ⁇ m. In general, the thickness of zone A3 is thus approx. 50% of the total wall thickness.
- the layer thicknesses of zones A1, A2, A3 are designed in relation to the total wall thickness.
- An increase of the total wall thickness by e.g. 100% will also increase the layer thickness of the individual zones by approx. 100%, wherein the relationships of the layer thicknesses to one another remain constant.
- the relationships of the layers to one another alter, in particular the layer thickness of layer A2 turns out to be relatively less than in the case of thinner-walled membranes.
- the capillary membrane according to the invention consisting of two co-extruded layers A and B is, as already stated above, the different pore size or mesh size in layers A and B, wherein the mesh size of the meshes in layer B is not only larger relative to the pore size of the above-mentioned outermost zone of layer A of zone A1, but also relative to all the pores of the whole of layer A.
- the two layers A and B perform different functions according to the invention:
- the outer layer A gives the hollow fibre membrane according to the invention its mechanical stability, in particular also when producing the membrane using the method according to the invention, which is described in detail below. Furthermore, this layer has the zone with the smallest average pore diameter (greater than 200 nm) in the whole membrane and is therefore the layer that determines selection with regard to filtration. The function of layer A is therefore to give the membrane according to the invention stability and selectivity.
- the layer B preferably arranged on the inside, i.e. the layer facing the blood or another bodily fluid, has in its net-like structure a mesh size that is much greater than the pore size of layer A. Not least because of its net-like or non-woven type structure and the resultant low mass density, this layer has almost no mechanical strength and must therefore be supported by the additional layer A.
- Layer B has the task in the blood treatment process of merely holding back the cellular components of the fluid to be passed through it.
- This layer therefore essentially has the function of compatibilizing the fluid to be filtered and the membrane with each other.
- the non-woven type structure and the concomitant high porosity of layer B further result, surprisingly, in an improved screening coefficient which is constant over the course of the treatment for high-molecular-weight components of blood, such as e.g. triglycerides or lipoproteins. It was shown that the screening coefficients remain essentially constant over a longer course of treatment, unlike plasma membranes known until now. Thus it is established in the case of plasma membranes known until now that the pores of the inner surface can be clogged by large blood lipid particles present in the blood. As a result, it is observed that the screening coefficients drop, since there is a smaller total flow-through passage through the membrane wall and the effective permeability drops. On the other hand, the porosity of the membrane according to the invention is so great on the blood-contact side that there are enough fluid passages, even by adsorption of the large blood lipid particles, to maintain the desired permeability.
- the ratio of the layer thicknesses of layer A to layer B is 4:1 to 6:1, with the result that layer A in particular can perform its supportive stability function particularly well.
- Typical total wall thicknesses of the hollow fibre membranes according to the invention are 40 to 80 ⁇ m, quite particularly preferably 60 ⁇ m.
- Such membranes according to the invention are typically used in fibre bundle sizes of 1300 to 2600 fibres for the production of plasma filters with membrane surfaces of 0.3 and 0.6 m 2 .
- the membrane surface also determines the physical parameters of the membrane: a plasma filter with a bundle consisting of a large number of hollow fibre membranes according to the invention (“hollow fibre bundle”) with a total membrane surface of 0.3 m 2 is provided for use with blood flows of 100 ml per minute and filtrate flows of up to 30 ml/m, the plasma filter with a membrane surface of 0.6 m 2 for blood flows of 200 ml per minute and filtrate flows of up to 3 ml/min.
- Each layer consists of a polymer mixture of at least two polymers selected from polysulfone (PSU), polyvinylpyrrolidone (PVP), polyethersulfone (PES), polyetherimide (PEI), polyamide (PA), polycarbonate (PC), polystyrene (PS), polymethyl methacrylate (PMMA), polyvinylidene fluoride (PVDF), polyacrylonitrile (PAN), polyimide (PI) and/or polyurethane (PU).
- PSU polysulfone
- PVP polyvinylpyrrolidone
- PES polyethersulfone
- PEI polyetherimide
- PA polyamide
- PC polycarbonate
- PS polystyrene
- PMMA polymethyl methacrylate
- PVDF polyvinylidene fluoride
- PAN polyacrylonitrile
- PI polyimide
- PU polyurethane
- a combination of polysulfone and polyvinylpyrrolidone is quite particularly preferred.
- the concentration of both components in the different layers can be set independently of each other in accordance with what is required of the membrane structure.
- a high polymer concentration for the outer layer results in high viscosities in the not yet precipitated out membrane, and thus in particular a low porosity, and a low polymer concentration for the inner layer B results in highly porous non-woven type membrane structures.
- the object of the present invention is also achieved by a method for the production of a hollow fibre membrane according to the invention, comprising the steps of
- the setting of the precipitation temperature at more than 70° C., in particular more than 75° C. makes possible a higher degree of moisture in the area around the precipitation slit, with the result that pores with a small diameter form on the outside of the membrane, in particular in the outermost layer described according to the invention.
- the viscosity of the spinning masses is thus also set depending on the proportion of the individual components. This is dependent on the molecular weight of the individual components.
- the viscosity of the spinning mass solution A is 7000 to 18000 mPa ⁇ s, in particular 9000 to 14000 mPa ⁇ s, depending on the desired membrane structure.
- the spinning mass solution A typically contains 15 to 25% polysulfone (PSU), 4 to 8% polyvinylpyrrolidone (PVP) and 81-67% solvent (98-100% DMAC and 0-2% water). 17.5-22.5% PSU, 5-8% PVP is preferred, the remainder being solvent (80-100% DMAC and 0-20% water). 19-21% PSU, 5.5-7% PVP is quite particularly preferred, the remainder being solvent (98-100% DMAC, 2-0% water). Unless otherwise indicated, the percentages always refer to wt.-%.
- the viscosity was determined by means of a rotating viscometer (Haake VT 550) which was temperature-controlled at 400 by means of the following instructions:
- the test substance was located in the annular slit between concentrically arranged cylinders, the “rotating body” and “measuring cup”.
- the rotational speed was preset and the effective force (shear stress) measured.
- the temperature-control vessel and the rotating body MV-DIN were first screwed to the basic structure. The zero point was then checked and set.
- the torque motor was switched off and the torque display set to zero with the button provided for the purpose.
- the measuring cup was filled up to the corresponding fill mark with the air-bubble-free test solution and fixed in the temperature-control vessel with the locking screw connection.
- the rotational speed stage was then preset. The programme was set and the viscosity read after the expiry of the measuring time.
- the rotational speed stage 3 was selected on the device for the measurement.
- the measurement lasted 30 min.
- the viscosity value was read after the pre-setting of the programme set in the apparatus.
- the programme S1 was selected for measurements in manual mode.
- the viscosity of spinning mass solution B is preferably less than 1000 mPa ⁇ s and it contains 5 to 15% polysulfone, 4 to 8% polyvinylpyrrolidone and 91-77% solvent (100% DMAC). 7-13% PSU, 4-7% PVP is preferred, the remainder being solvent (100% DMAC). 8-12% PSU, 5-7% PVP is quite particularly preferred, the remainder being solvent (100% DMAC).
- the finished membrane contains approx. 3% PVP after the rinsing and drying steps. This PVP is bound and only minimally elutable.
- the viscosity of the spinning mass solution B care must also be taken that the viscosity is not too low, typically not less than 300 mPa ⁇ s, since otherwise the so-called beading phenomenon, which represents a preliminary stage to dripping, will occur. In this case the precipitant no longer flows uniformly, whereby the internal diameter changes in rapid succession, with the result that the hollow fibre takes on the appearance of a string of beads.
- the spinning mass solution B has a viscosity of less than 300, in particular less than 200, mPa ⁇ s and is precipitated softly.
- “precipitated softly” means that there is a large proportion of solvent in the precipitant of the precipitation or coagulation bath, resulting in a slow coagulation of the polymer thread and leading to larger pores.
- the size of the membrane i.e. also the wall thickness and the internal diameter
- the wall thickness is typically 10 to 70 ⁇ m and in the ultrafiltration application the wall thickness can be some 100s ⁇ m, e.g. 1000 ⁇ m, wherein the dimensions can be increased or decreased by a person skilled in the art.
- the desired non-woven type, large-pored structure of layer B according to the invention forms using the method according to the invention.
- a precipitant e.g. a mixture of dimethylacetamide (DMAC) and water, for example 70% DMAC and 30% water, preferably 80% DMAC and 20% water
- the precipitation rate is also particularly important; it is set by the spinning speed of 200 to 400 mm per second, quite particularly preferably 200 to 250 mm per second, and also by a precipitation slit height of 5 to 50 mm.
- the spinning mass In order to produce the necessary large pores in layer B, the spinning mass must be precipitated slowly, with the result that the resultant hollow fibre membrane remains very soft and mechanically unstable in the precipitation slit.
- the soft precipitant cannot pass through the whole membrane wall and the membrane enters the precipitation bath (or coagulation bath), without pores already having formed on the outside.
- the formation of the pores on the outside is, as already explained above, initiated by as high as possible a degree of moisture in the area around the precipitation slit which is set by the temperature of the precipitation bath.
- the polymer fibre is preferably guided in an enclosure (e.g. a pipe or the like) as far as the surface of the precipitation bath.
- the degree of moisture can be regulated in the enclosure.
- the membrane obtained according to the invention still contains large quantities of extractable free polyvinylpyrrolidone in a quantity of approx. 1 g/m 2 . This is rinsed out with a solvent, such as e.g. water, in a rinsing bath.
- a solvent such as e.g. water
- the temperature of the rinsing bath is typically kept in the range of 60 to 80° C.
- the membrane must, as far as possible, be freed of polyvinylpyrrolidone, since otherwise elutable PVP can enter the blood circulation. This can preferably also be avoided through drying temperatures of the membrane obtained according to the invention in the range of 80 to 110, in particular 90 to 100° C.
- hollow fibre membrane according to the invention for separation processes in the nanofiltration and ultrafiltration ranges, in particular for haemodialysis and haemodiafiltration and haemofiltration.
- the two-component membranes according to the invention have good mechanical properties, such as strength, high breaking elongation in the dry state.
- the membranes can be housed dry in the filter module and dispatched dry.
- the fact that filter modules equipped with the hollow fibre according to the invention can be wetted directly by blood is particularly important for the blood treatment application method.
- FIG. 1 an REM photograph of layer B magnified 1000 ⁇
- FIG. 2 an REM photograph of layer B magnified 5000 ⁇
- FIG. 3 an REM photograph of layer A of a hollow fibre membrane according to the invention
- FIG. 4 an REM photograph of the cross-section through a hollow fibre membrane according to the invention.
- FIG. 5 an REM photograph of a longitudinal section through a hollow fibre membrane according to the invention.
- a hollow fibre membrane according to the invention was prepared, wherein the spinning mass solution A consisted of 20% polysulfone (Solvay, UDEL P-3500 LCD), 6% polyvinylpyrrolidone (ISP, PVP K-90) and 1% water, the remainder being dimethylacetamide, and the spinning mass solution B for the inner layer B consisted of 10 wt.-% polysulfone, 5.5% polyvinylpyrrolidone, the remainder being dimethylacetamide.
- the spinning mass solution A consisted of 20% polysulfone (Solvay, UDEL P-3500 LCD), 6% polyvinylpyrrolidone (ISP, PVP K-90) and 1% water, the remainder being dimethylacetamide
- the spinning mass solution B for the inner layer B consisted of 10 wt.-% polysulfone, 5.5% polyvinylpyrrolidone, the remainder being dimethylacetamide.
- the precipitant consisted of 80% dimethylacetamide and 20% water.
- the spinning block temperature was set to 60° C.
- the precipitation slit height was 30 mm and the spinning speed 250 mm per second.
- the temperature of the precipitation bath was approx. 80° C.
- the REM photographs were produced by means of a scanning electron microscope customary in the trade.
- FIGS. 1 and 2 show REM photographs magnified 1000 ⁇ ( FIG. 1 ) and 5000 ⁇ ( FIG. 2 ) of layer B, in other words of the inside of the hollow fibre membrane according to the invention.
- FIG. 3 shows an REM photograph magnified 5000 ⁇ of the outside of the hollow fibre membrane according to the invention (layer A) with an average pore size of approx. 1 ⁇ m as a result of the high moisture content in the precipitation slit during precipitation. Overall, a very high pore density can be seen with a small portion of matrix material.
- FIG. 4 an REM photograph magnified 1600 ⁇ of the cross-section through a hollow fibre membrane according to the invention which has been exposed by so-called “cryofracture” is shown.
- “Cryofracture” means that the hollow fibre membrane according to the invention is immersed in liquid nitrogen and then broken manually in the lateral direction.
- the two-layered structure of the membrane according to the invention can be seen from FIG. 4 wherein, because of the zonal structure of layer A, a clear boundary line between the two layers A and B is not very markedly pronounced, but both pass gradually into each other via the gradients obtained according to the invention in the individual zones of layer A.
- the ultrafiltration rate, the screening coefficients and the permeability were also measured.
- FIG. 5 an REM photograph magnified 200 ⁇ of the longitudinal section through a hollow fibre membrane according to the invention is shown.
- the longitudinal section is obtained by cutting through the hollow fibre according to the invention in longitudinal direction with a suitable cutting device, for example a so-called microtome knife.
- a suitable cutting device for example a so-called microtome knife.
- the irregular structures in the hollow fibre membrane wall stem from the cutting channels of the microtome knife.
- the non-woven type network structure of the inside of the hollow fibre membrane according to the invention can be readily recognized in FIG. 5 .
- UF V filtrate ⁇ 3600)/ t ⁇ (( ⁇ in + ⁇ out )/2) ⁇ 0.75) by means of a dialysis tube system known from the state of the art, wherein UF represents the ultrafiltration rate in (ml/(h ⁇ mm Hg), V filtrate the filtrate volume in ml (in the present case: 1000 ml), t the time in seconds (to filter 1000 ml), ⁇ in the pressure of the blood-side intake (mbar) and ⁇ out the pressure of the blood-side run-out (mbar) at the device.
- the blood outlet (blood-side run-out) was closed during the measurement, with the result that only filtration occurred.
- the polyvinylpyrrolidone residue from the membrane according to the invention according to an extract from the end-product was ⁇ 1 mg.
- the last value is therefore advantageous in particular because the hollow fibre membrane according to the invention is thus used in particular in dialysis treatments which are carried out over very long periods of time.
- the membrane according to the invention can be used for membrane pheresis treatments, where limit values of up to 5 mg release polyvinylpyrrolidone per filter with 0.6-m 2 membrane surface determined using the method below are reasonable.
- the membrane according to the invention lies well below this limit value.
- Residues other than polyvinylpyrrolidone were not able to be discovered in the extract from the filter.
- the polyvinylpyrrolidone was extracted according to the following instructions:
- Sample no. 1 consisted of a fibre bundle (total membrane surface 0.6 m 2 ), as did sample 2. Each plasma filter was extracted with 1000 ml water at 370 Celsius recirculating over 90 minutes.
- the flow at the blood-side inlet of the plasma filter was 200 ml. 60 ml/min. thereof was filtered and 140 ml/min. flowed back out of the filter at the blood-side outlet.
- the measured values in mg/l also corresponded to the values for mg/filter.
- the concentration of polyvinylpyrrolidone was determined by means of quantitative IR spectroscopy and had a value of 0.86 to 0.90 mg/filter.
- the CO oscillation band in the wave number range of 1630-1735 cm ⁇ 1 was used.
- the values for elutable PVP in both samples are thus less than 1 mg/filter, whereby the hollow fibre membrane according to the invention thus also meets strict requirements in relation to elutable PVP.
- Customary acceptable elutable PVP quantities of less than 5 mg are acceptable, values smaller than 3 mg/filter are preferred, smaller than 2 mg/filter even more preferred, less than 1 mg/filter quite particularly preferred.
- the total PVP content of the finished hollow fibre membrane is approx. 3% (percent by weight). The determination was carried out for example via infrared spectroscopy or pyrolysis gas chromatography with nitrogen and sulphur detection.
Abstract
Description
- The present invention relates to a hollow fibre capillary membrane and a method for the production thereof plus its use in particular in plasmapheresis.
- Capillary membranes of different compositions are known in particular because of their increasing use in dialysis or also in plasmapheresis. The use and the production of membranes, in particular of capillary membranes, in dialysis is described for example in the publication by Samtleben and Lysaght in: Horl et al. Replacement of Renal Function by Dialysis 5th ed., Kluwer, 2004, pp. 709 to 724.
- Thus WO 96/37282 describes a membrane, in particular for haemodialysis, which has a separating layer with a cut-off between 500 and 5000000 dalton, a supporting layer and a layer co-determining the hydraulic permeability, wherein the separation limit and hydraulic permeability are set mutually independently. However, it is very expensive to build up the membrane with different pore sizes within the individual layers.
- EP 1547628 A1 describes plasma purification membranes and a plasma purification system, and in particular is geared towards specific physical properties, in particular the breaking resistance of the membrane due to the high stress load during plasma purification. This involves in particular protein and immunoglobulin permeability. In the membrane with a sponge-like structure, a gradient of the pore size is set, wherein a larger pore size is to be found on the outer surface than on the inner surface of the membrane.
- U.S. Pat. No. 6,565,782 relates to synthetic polymeric microfiltration membrane materials with high surface porosity which can be obtained by co-casting a sulfone polymer with a hydrophilic polymer, such as polyvinylpyrrolidone. Disadvantages occur with this membrane in particular in relation to the separation of cellular components of the blood from the plasma phase, since the pressure on the blood cells caused by the use of small-pored membranes can lead to damage to the blood cells.
- So-called hollow fibre spinnerets are used in most cases to produce such capillary membranes. An overview of this and other techniques for the production of hollow fibre membranes is disclosed in M. Mulder, Basic Principles of Membrane Technology second ed., Kluwer 1996, pp. 71-91.
- When a hollow fibre membrane is produced by means of a hollow fibre spinneret, the hollow fibre membrane is produced in a so-called precipitation spinning process, wherein the polymers to be precipitated emerge from an annular slit of a spinneret arrangement, while the corresponding precipitant flows out of a central precipitant bore.
- A hollow fibre spinneret of the named type is disclosed for example in DE A1.
- Typical plasmapheresis filters of the state of the art contain in most cases hydrophobic membranes, for example of polypropylene, polysulfone, etc.
- Since these hydrophobic membranes cannot be wetted with water, the filters containing these membranes are typically made hydrophilic with water under pressure. For the subsequent blood treatment, it is therefore ensured that all the air inclusions inside the pores have been expelled and therefore do not enter the blood circulation. Disadvantageously, these filter modules with hydrophobic hollow fibre membranes must be delivered filled with water to the clients and patients. Attempts are being made to circumvent the raw material and distribution costs and the difficulty of guaranteeing the sterility of such filled modules.
- Problems with the plasma membranes known until now are their low permeability for large lipoproteins and pressure-induced damage to blood cells due to the transmembrane pressure difference, i.e. due to the negative pressures acting on a blood cell adhering to the membrane wall and adjacent to a pore opening. The lower the pore size is, the greater, with a given transmembrane pressure difference (TMP), the pressure difference acting on a blood cell that is large relative to the pore size is on the affected section of the blood cell. In such cases, it has often been shown that the pressure acting on the corresponding section of the blood cell is so great that the blood cell walls burst, leading to haemolysis. Attempts are therefore being made to produce as high as possible a porosity on the blood-side membrane wall surface, with the result that the negative pressure impact on the blood cell wall is distributed over a larger surface area of the blood cell.
- Because of the low permeability for large lipoproteins of the membranes known from the state of the art, difficulties arise with these in particular during the filtration of lipaemic blood due to the drop in the screening coefficients. Hydrophobic plasma membranes often display, in blood treatment, the negative property of clogging in the course of the treatment due to interaction with the nonpolar blood lipids. A drop in the screening coefficient is therefore often observed during the blood treatment.
- It was therefore an object of the present invention to provide a hollow fibre membrane which in particular makes possible a gentle plasmapheresis, in particular a gentle plasma filtration of blood. Furthermore, such a hollow fibre membrane should also have, in addition to the largest possible openings for a good lipoprotein permeability with a simultaneously high selectivity, a high porosity for an improved blood compatibility.
- According to the invention, this object is achieved by an integral hollow fibre membrane, consisting of two co-extruded layers A and B, wherein layer B has a non-woven type structure with a mesh size of 0.1 to 10 μm and layer A has a porous structure. By “mesh size” is meant in this connection the greatest distance, in a non-woven type or net-like structure, between the individual branchings of the structure forming the non-woven material or net. The thickness of the webs of the branching is 0.1-0.5 μm in this case.
- Layer B preferably forms the so-called blood-contact side and layer A the filtrate side of the hollow fibre membrane, for example in a blood treatment in which the blood is passed through the inside of the hollow fibre.
- As a rule, the blood-contact side is the inner layer of the hollow fibre membrane and layer A, thus the filtrate side, is the outer layer of the membrane. In less preferred embodiments, however, it is also possible for layer B to be the outer layer (the blood-contact side) and layer A the inner layer (filtrate side).
- Because of the membrane according to the invention and in particular the presence of the non-woven type inner layer B, a lower negative pressure acts on a section of a blood cell through the transmembrane pressure difference than in the case of a small-pored membrane of the state of the art, with the result that in particular the cellular components of the blood can be separated particularly gently from the plasma phase of the blood.
- It is preferred that layer A consists of at least three successive zones A1, A2, A3 of different porosity, wherein zone A1 forms the surface of layer A and has pores with an average pore size of 0.7 to 2 μm. The thickness of zone A1 typically lies in the range of 9 to 11 μm, and is preferably 10 μm, with a preferred wall thickness of approx. 60 μm.
- Adjoining this is zone A2 which is arranged between zones A1 and A3 and has an average pore size of more than 200 nm.
- The thickness of this zone A2 is typically approx. 10 μm, with a preferred total wall thickness of 60 μm. In general, the thickness of zone A2 is thus approximately ⅙ of the total wall thickness.
- A third zone A3 is directly adjacent to layer B and is typically positively connected to the non-woven type structure of layer B. Zone A3 has a pore-size gradient towards layer B, i.e. the pore size increases towards layer B. The thickness of zone A3 is approx. 30 μm for a total wall thickness of 60 μm. In general, the thickness of zone A3 is thus approx. 50% of the total wall thickness.
- The layer thicknesses of zones A1, A2, A3 are designed in relation to the total wall thickness. An increase of the total wall thickness by e.g. 100% will also increase the layer thickness of the individual zones by approx. 100%, wherein the relationships of the layer thicknesses to one another remain constant. In the transition to even greater layer thicknesses of the total wall thickness, however, it was established during production that the relationships of the layers to one another alter, in particular the layer thickness of layer A2 turns out to be relatively less than in the case of thinner-walled membranes.
- Important for the capillary membrane according to the invention consisting of two co-extruded layers A and B is, as already stated above, the different pore size or mesh size in layers A and B, wherein the mesh size of the meshes in layer B is not only larger relative to the pore size of the above-mentioned outermost zone of layer A of zone A1, but also relative to all the pores of the whole of layer A.
- The two layers A and B perform different functions according to the invention:
- Because of its greater mass density, the outer layer A gives the hollow fibre membrane according to the invention its mechanical stability, in particular also when producing the membrane using the method according to the invention, which is described in detail below. Furthermore, this layer has the zone with the smallest average pore diameter (greater than 200 nm) in the whole membrane and is therefore the layer that determines selection with regard to filtration. The function of layer A is therefore to give the membrane according to the invention stability and selectivity.
- The layer B, preferably arranged on the inside, i.e. the layer facing the blood or another bodily fluid, has in its net-like structure a mesh size that is much greater than the pore size of layer A. Not least because of its net-like or non-woven type structure and the resultant low mass density, this layer has almost no mechanical strength and must therefore be supported by the additional layer A. Layer B has the task in the blood treatment process of merely holding back the cellular components of the fluid to be passed through it.
- Because of the non-woven type structure of this layer, it was surprisingly shown that this takes place in an unexpectedly gentle manner vis-à-vis the cells. This layer therefore essentially has the function of compatibilizing the fluid to be filtered and the membrane with each other.
- The non-woven type structure and the concomitant high porosity of layer B further result, surprisingly, in an improved screening coefficient which is constant over the course of the treatment for high-molecular-weight components of blood, such as e.g. triglycerides or lipoproteins. It was shown that the screening coefficients remain essentially constant over a longer course of treatment, unlike plasma membranes known until now. Thus it is established in the case of plasma membranes known until now that the pores of the inner surface can be clogged by large blood lipid particles present in the blood. As a result, it is observed that the screening coefficients drop, since there is a smaller total flow-through passage through the membrane wall and the effective permeability drops. On the other hand, the porosity of the membrane according to the invention is so great on the blood-contact side that there are enough fluid passages, even by adsorption of the large blood lipid particles, to maintain the desired permeability.
- In order to give the membrane the optimum properties as regards stability and selectivity, the ratio of the layer thicknesses of layer A to layer B is 4:1 to 6:1, with the result that layer A in particular can perform its supportive stability function particularly well.
- It was shown that an internal diameter of 280 to 400 μm is advantageous for the planned use, in order to withstand even more pronounced pressures and pressure differences. Typical total wall thicknesses of the hollow fibre membranes according to the invention are 40 to 80 μm, quite particularly preferably 60 μm. Such membranes according to the invention are typically used in fibre bundle sizes of 1300 to 2600 fibres for the production of plasma filters with membrane surfaces of 0.3 and 0.6 m2.
- The membrane surface also determines the physical parameters of the membrane: a plasma filter with a bundle consisting of a large number of hollow fibre membranes according to the invention (“hollow fibre bundle”) with a total membrane surface of 0.3 m2 is provided for use with blood flows of 100 ml per minute and filtrate flows of up to 30 ml/m, the plasma filter with a membrane surface of 0.6 m2 for blood flows of 200 ml per minute and filtrate flows of up to 3 ml/min.
- Each layer consists of a polymer mixture of at least two polymers selected from polysulfone (PSU), polyvinylpyrrolidone (PVP), polyethersulfone (PES), polyetherimide (PEI), polyamide (PA), polycarbonate (PC), polystyrene (PS), polymethyl methacrylate (PMMA), polyvinylidene fluoride (PVDF), polyacrylonitrile (PAN), polyimide (PI) and/or polyurethane (PU).
- A combination of polysulfone and polyvinylpyrrolidone is quite particularly preferred.
- The concentration of both components in the different layers can be set independently of each other in accordance with what is required of the membrane structure. A high polymer concentration for the outer layer results in high viscosities in the not yet precipitated out membrane, and thus in particular a low porosity, and a low polymer concentration for the inner layer B results in highly porous non-woven type membrane structures.
- The object of the present invention is also achieved by a method for the production of a hollow fibre membrane according to the invention, comprising the steps of
-
- (a) preparing two spinning mass solutions A and B, wherein the viscosity of spinning mass solution A is higher than the viscosity of spinning mass solution B,
- (b) setting the precipitation bath temperature at more than 70° C.,
- (c) bringing the two spinning mass solutions A and B into contact with an internal precipitant through a hollow fibre spinneret,
- (d) precipitating the hollow fibre membrane.
- The setting of the precipitation temperature at more than 70° C., in particular more than 75° C., makes possible a higher degree of moisture in the area around the precipitation slit, with the result that pores with a small diameter form on the outside of the membrane, in particular in the outermost layer described according to the invention.
- The viscosity of the spinning masses is thus also set depending on the proportion of the individual components. This is dependent on the molecular weight of the individual components.
- The viscosity of the spinning mass solution A is 7000 to 18000 mPa·s, in particular 9000 to 14000 mPa·s, depending on the desired membrane structure. The spinning mass solution A typically contains 15 to 25% polysulfone (PSU), 4 to 8% polyvinylpyrrolidone (PVP) and 81-67% solvent (98-100% DMAC and 0-2% water). 17.5-22.5% PSU, 5-8% PVP is preferred, the remainder being solvent (80-100% DMAC and 0-20% water). 19-21% PSU, 5.5-7% PVP is quite particularly preferred, the remainder being solvent (98-100% DMAC, 2-0% water). Unless otherwise indicated, the percentages always refer to wt.-%.
- The viscosity was determined by means of a rotating viscometer (Haake VT 550) which was temperature-controlled at 400 by means of the following instructions:
- In the viscosity measurement, the test substance was located in the annular slit between concentrically arranged cylinders, the “rotating body” and “measuring cup”. The rotational speed was preset and the effective force (shear stress) measured. The temperature-control vessel and the rotating body MV-DIN were first screwed to the basic structure. The zero point was then checked and set. The torque motor was switched off and the torque display set to zero with the button provided for the purpose. For the actual measurement, the measuring cup was filled up to the corresponding fill mark with the air-bubble-free test solution and fixed in the temperature-control vessel with the locking screw connection. The rotational speed stage was then preset. The programme was set and the viscosity read after the expiry of the measuring time.
- The rotational speed stage 3 was selected on the device for the measurement. The measurement lasted 30 min. The viscosity value was read after the pre-setting of the programme set in the apparatus. The programme S1 was selected for measurements in manual mode.
- The viscosity of spinning mass solution B is preferably less than 1000 mPa·s and it contains 5 to 15% polysulfone, 4 to 8% polyvinylpyrrolidone and 91-77% solvent (100% DMAC). 7-13% PSU, 4-7% PVP is preferred, the remainder being solvent (100% DMAC). 8-12% PSU, 5-7% PVP is quite particularly preferred, the remainder being solvent (100% DMAC).
- The finished membrane contains approx. 3% PVP after the rinsing and drying steps. This PVP is bound and only minimally elutable.
- Important in this connection, as shown above, is the different viscosity of the two spinning mass solutions A and B, resulting in the different porosity in the two co-extruded layers A and B of the hollow fibre membrane according to the invention.
- In relation to the viscosity of the spinning mass solution B, care must also be taken that the viscosity is not too low, typically not less than 300 mPa·s, since otherwise the so-called beading phenomenon, which represents a preliminary stage to dripping, will occur. In this case the precipitant no longer flows uniformly, whereby the internal diameter changes in rapid succession, with the result that the hollow fibre takes on the appearance of a string of beads. This occurs in particular when the spinning mass solution B has a viscosity of less than 300, in particular less than 200, mPa·s and is precipitated softly. In this connection, “precipitated softly” means that there is a large proportion of solvent in the precipitant of the precipitation or coagulation bath, resulting in a slow coagulation of the polymer thread and leading to larger pores.
- Within the framework of the invention, the size of the membrane, i.e. also the wall thickness and the internal diameter, can be varied within relatively wide ranges, whereby it is possible to adapt the membrane to different intended uses. For haemodialysis, haemodiafiltration and haemofiltration, and also in plasmapheresis, the wall thickness is typically 10 to 70 μm and in the ultrafiltration application the wall thickness can be some 100s μm, e.g. 1000 μm, wherein the dimensions can be increased or decreased by a person skilled in the art.
- During precipitation with a precipitant, e.g. a mixture of dimethylacetamide (DMAC) and water, for example 70% DMAC and 30% water, preferably 80% DMAC and 20% water, the desired non-woven type, large-pored structure of layer B according to the invention forms using the method according to the invention.
- The precipitation rate is also particularly important; it is set by the spinning speed of 200 to 400 mm per second, quite particularly preferably 200 to 250 mm per second, and also by a precipitation slit height of 5 to 50 mm.
- In order to produce the necessary large pores in layer B, the spinning mass must be precipitated slowly, with the result that the resultant hollow fibre membrane remains very soft and mechanically unstable in the precipitation slit.
- In the range of the spinning speed set according to the invention, the soft precipitant cannot pass through the whole membrane wall and the membrane enters the precipitation bath (or coagulation bath), without pores already having formed on the outside. The formation of the pores on the outside is, as already explained above, initiated by as high as possible a degree of moisture in the area around the precipitation slit which is set by the temperature of the precipitation bath. After emerging from the extrusion die, the polymer fibre is preferably guided in an enclosure (e.g. a pipe or the like) as far as the surface of the precipitation bath. The degree of moisture can be regulated in the enclosure.
- The membrane obtained according to the invention still contains large quantities of extractable free polyvinylpyrrolidone in a quantity of approx. 1 g/m2. This is rinsed out with a solvent, such as e.g. water, in a rinsing bath.
- The temperature of the rinsing bath is typically kept in the range of 60 to 80° C. The membrane must, as far as possible, be freed of polyvinylpyrrolidone, since otherwise elutable PVP can enter the blood circulation. This can preferably also be avoided through drying temperatures of the membrane obtained according to the invention in the range of 80 to 110, in particular 90 to 100° C.
- Other subjects of the present invention are the use of the hollow fibre membrane according to the invention for separation processes in the nanofiltration and ultrafiltration ranges, in particular for haemodialysis and haemodiafiltration and haemofiltration.
- The two-component membranes according to the invention have good mechanical properties, such as strength, high breaking elongation in the dry state. The membranes can be housed dry in the filter module and dispatched dry. The fact that filter modules equipped with the hollow fibre according to the invention can be wetted directly by blood is particularly important for the blood treatment application method.
- The invention is explained in more detail by means of the figures and an embodiment example, but these are not to be considered limiting.
- There are shown in
-
FIG. 1 : an REM photograph of layer B magnified 1000×, -
FIG. 2 : an REM photograph of layer B magnified 5000×, -
FIG. 3 : an REM photograph of layer A of a hollow fibre membrane according to the invention, -
FIG. 4 : an REM photograph of the cross-section through a hollow fibre membrane according to the invention, and -
FIG. 5 : an REM photograph of a longitudinal section through a hollow fibre membrane according to the invention. - A hollow fibre membrane according to the invention was prepared, wherein the spinning mass solution A consisted of 20% polysulfone (Solvay, UDEL P-3500 LCD), 6% polyvinylpyrrolidone (ISP, PVP K-90) and 1% water, the remainder being dimethylacetamide, and the spinning mass solution B for the inner layer B consisted of 10 wt.-% polysulfone, 5.5% polyvinylpyrrolidone, the remainder being dimethylacetamide.
- The precipitant consisted of 80% dimethylacetamide and 20% water.
- A spinning nozzle according to DE 10211051, incorporated in a spinning block, was used as spinning nozzle.
- The spinning block temperature was set to 60° C. The precipitation slit height was 30 mm and the spinning speed 250 mm per second.
- The temperature of the precipitation bath was approx. 80° C.
- After precipitation and drying, the thus-obtained hollow fibre membrane according to the invention was examined by means of REM photographs.
- The REM photographs were produced by means of a scanning electron microscope customary in the trade.
-
FIGS. 1 and 2 show REM photographs magnified 1000× (FIG. 1 ) and 5000× (FIG. 2 ) of layer B, in other words of the inside of the hollow fibre membrane according to the invention. - Both photographs show the non-woven type structure of layer B which is built up from many net-like struts (webs). This non-woven type structure is not a typical porous structure in the conventional sense, such as is present in layer A for example.
-
FIG. 3 shows an REM photograph magnified 5000× of the outside of the hollow fibre membrane according to the invention (layer A) with an average pore size of approx. 1 μm as a result of the high moisture content in the precipitation slit during precipitation. Overall, a very high pore density can be seen with a small portion of matrix material. - In
FIG. 4 , an REM photograph magnified 1600× of the cross-section through a hollow fibre membrane according to the invention which has been exposed by so-called “cryofracture” is shown. “Cryofracture” means that the hollow fibre membrane according to the invention is immersed in liquid nitrogen and then broken manually in the lateral direction. - The two-layered structure of the membrane according to the invention can be seen from
FIG. 4 wherein, because of the zonal structure of layer A, a clear boundary line between the two layers A and B is not very markedly pronounced, but both pass gradually into each other via the gradients obtained according to the invention in the individual zones of layer A. - The ultrafiltration rate, the screening coefficients and the permeability were also measured.
- In
FIG. 5 , an REM photograph magnified 200× of the longitudinal section through a hollow fibre membrane according to the invention is shown. - The longitudinal section is obtained by cutting through the hollow fibre according to the invention in longitudinal direction with a suitable cutting device, for example a so-called microtome knife.
- In the figure, the irregular structures in the hollow fibre membrane wall stem from the cutting channels of the microtome knife.
- The non-woven type network structure of the inside of the hollow fibre membrane according to the invention can be readily recognized in
FIG. 5 . - Ultrafiltration Rate
- The aqueous ultrafiltration rate of the hollow fibre membrane according to the invention was determined using the following equation
UF=V filtrate×3600)/t×((ρin+ρout)/2)×0.75)
by means of a dialysis tube system known from the state of the art, wherein UF represents the ultrafiltration rate in (ml/(h×mm Hg), Vfiltrate the filtrate volume in ml (in the present case: 1000 ml), t the time in seconds (to filter 1000 ml), ρin the pressure of the blood-side intake (mbar) and ρout the pressure of the blood-side run-out (mbar) at the device. - The blood outlet (blood-side run-out) was closed during the measurement, with the result that only filtration occurred.
- An ultrafiltration value (UF value) in the range of 4500 to 5000 ml/h×mmHg×m2 was measured for the membranes according to the invention (surface area 0.6 m2).
- Screening Coefficient
- 1000 ml lipaemic whole blood with a triglyceride content of 200-300 mg/dl was used for a module with a surface area of 0.6 m2. This blood is circulated through the lumen of the fibre for one hour at a blood flow of 200 ml/min. During this time, a filtrate flow of 60 ml/min is simultaneously filtered to the outside through the fibre wall. The screening coefficient for LDLs (low-density lipoproteins) under these conditions is at least 90%, typically 95-100%, mostly 99%. The screening coefficient for LDLs remains constant over a period of time corresponding to at least the period of time for the blood treatment of a common plasma filtration.
- Free Polyvinylpyrrolidone Content
- The polyvinylpyrrolidone residue from the membrane according to the invention according to an extract from the end-product was <1 mg. The last value is therefore advantageous in particular because the hollow fibre membrane according to the invention is thus used in particular in dialysis treatments which are carried out over very long periods of time. In particular, the membrane according to the invention can be used for membrane pheresis treatments, where limit values of up to 5 mg release polyvinylpyrrolidone per filter with 0.6-m2 membrane surface determined using the method below are reasonable. The membrane according to the invention lies well below this limit value.
- Residues other than polyvinylpyrrolidone were not able to be discovered in the extract from the filter.
- The polyvinylpyrrolidone was extracted according to the following instructions:
- Two plasma filters from the same batch were used in the extraction.
- Sample no. 1 consisted of a fibre bundle (total membrane surface 0.6 m2), as did sample 2. Each plasma filter was extracted with 1000 ml water at 370 Celsius recirculating over 90 minutes.
- The flow at the blood-side inlet of the plasma filter was 200 ml. 60 ml/min. thereof was filtered and 140 ml/min. flowed back out of the filter at the blood-side outlet.
- Both the water at the blood-side outlet and the filtrate were returned to the solvent reservoir.
- At the used volume of 1000 ml water, the measured values in mg/l also corresponded to the values for mg/filter.
- The results are shown in Table 1.
TABLE 1 Analysis values of hollow fibre membranes according to the invention Measurement Sample no. 2600- Sample no. 2600- Parameter method Unit S-0847-1 S-0847-2 PVP quantitative IR mg/filter 0.86 0.90 GC-volatile GC-MSD mg/l <0.10 <0.10 substances (as cyclohexanol - The concentration of polyvinylpyrrolidone was determined by means of quantitative IR spectroscopy and had a value of 0.86 to 0.90 mg/filter. For the evaluation, the CO oscillation band in the wave number range of 1630-1735 cm−1 was used.
- As can be seen from Table 1, the values for elutable PVP in both samples are thus less than 1 mg/filter, whereby the hollow fibre membrane according to the invention thus also meets strict requirements in relation to elutable PVP.
- Customary acceptable elutable PVP quantities of less than 5 mg are acceptable, values smaller than 3 mg/filter are preferred, smaller than 2 mg/filter even more preferred, less than 1 mg/filter quite particularly preferred.
- The total PVP content of the finished hollow fibre membrane is approx. 3% (percent by weight). The determination was carried out for example via infrared spectroscopy or pyrolysis gas chromatography with nitrogen and sulphur detection.
Claims (23)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1020070129051. | 2007-04-23 | ||
DE102007019051A DE102007019051B3 (en) | 2007-04-23 | 2007-04-23 | Hollow fiber capillary membrane and process for its preparation |
DE1020070129051.6 | 2007-04-23 | ||
DE1020070129051 | 2007-04-23 | ||
PCT/EP2008/003195 WO2008128749A1 (en) | 2007-04-23 | 2008-04-21 | Hollow fiber capillary membrane and method for the production thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
US20100163488A1 US20100163488A1 (en) | 2010-07-01 |
US20100326915A2 true US20100326915A2 (en) | 2010-12-30 |
US9149770B2 US9149770B2 (en) | 2015-10-06 |
Family
ID=39494983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/594,694 Active 2029-11-01 US9149770B2 (en) | 2007-04-23 | 2008-04-21 | Hollow fiber capillary membrane and method for the production thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US9149770B2 (en) |
EP (1) | EP2155368B1 (en) |
JP (1) | JP5010026B2 (en) |
CN (1) | CN101626821A (en) |
DE (1) | DE102007019051B3 (en) |
WO (1) | WO2008128749A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110263020A1 (en) * | 2008-09-25 | 2011-10-27 | Gambro Lundia Ab | Membrane for cell expansion |
US20110266223A1 (en) * | 2008-10-15 | 2011-11-03 | National University Of Singapore | Dual-layer hollow fibers with enhanced flux as forward osmosis membranes for water reuses and protein enrichment |
US20120067815A1 (en) * | 2008-09-25 | 2012-03-22 | Gambro Lundia Ab | Hybrid bioartificial kidney |
US20140284267A1 (en) * | 2011-10-04 | 2014-09-25 | Mn Beteiligungs Gmbh | Abrasion-proof filtration membrane and method of producing said membrane |
US10822461B2 (en) | 2017-10-05 | 2020-11-03 | Fresenius Medical Care Holdings, Inc. | Polysulfone-urethane copolymer, membranes and products incorporating same, and methods for making and using same |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102462866A (en) * | 2010-11-17 | 2012-05-23 | 于杰 | Composite semi-permeable membrane hemodialysis tank |
GB201019932D0 (en) * | 2010-11-24 | 2011-01-05 | Imp Innovations Ltd | Dimensional hollow fibre bioreactor systems for the maintenance, expansion, differentiation and harvesting of human stem cells and their progeny |
WO2013065819A1 (en) * | 2011-11-04 | 2013-05-10 | 旭化成メディカル株式会社 | Separation membrane for use in treatment of blood, and blood treatment device having said membrane integrated therein |
KR102090095B1 (en) | 2012-09-26 | 2020-03-17 | 도레이 카부시키가이샤 | Composite semipermeable membrane |
CN104069744B (en) * | 2014-07-21 | 2016-01-27 | 云南城投碧水源水务科技有限责任公司 | There is the enhancement type hollow fiber film of hydrophily honeycomb, its preparation method and process units |
US11311842B2 (en) * | 2015-12-28 | 2022-04-26 | Fenwal, Inc. | Membrane separation device having improved filtration velocity |
WO2017178482A1 (en) * | 2016-04-11 | 2017-10-19 | Basf Se | Porous thermoplastic membranes |
EP3803247A4 (en) * | 2018-06-11 | 2022-03-23 | The Regents of the University of Colorado, a body corporate | Single and multi-layer mesh structures for enhanced thermal transport |
CN108752824A (en) * | 2018-06-18 | 2018-11-06 | 北京点域科技有限公司 | A kind of preparation method of dialysis capillary fibers |
CN111455478B (en) * | 2020-04-10 | 2020-11-20 | 佛山市睿牛制衣有限公司 | Composite nanofiber membrane for fabric with high moisture-conducting and quick-drying functions, preparation method of composite nanofiber membrane and fabric |
DE102020206867A1 (en) | 2020-06-02 | 2021-12-02 | Fresenius Medical Care Deutschland Gmbh | HOLLOW FIBER MEMBRANE FOR THE SEPARATION OF BLOOD PLASMA FROM BLOOD |
CN113877441B (en) * | 2021-11-12 | 2024-02-23 | 江苏巨之澜科技有限公司 | Composite hollow fiber woven tube filter membrane for fuel cell and preparation method and application thereof |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933085A (en) * | 1987-05-20 | 1990-06-12 | Gkss-Forschungszentrum Geesthacht Gmbh | Method of manufacturing an integral asymmetrical membrane |
US5034129A (en) * | 1988-09-09 | 1991-07-23 | Stork Friesland B.V. | Membrane assembly |
US5141642A (en) * | 1987-10-09 | 1992-08-25 | Ube Industries, Ltd. | Aromatic polyimide double layered hollow filamentary membrane and process for producing same |
US5145583A (en) * | 1989-12-22 | 1992-09-08 | Hospal Industrie | Asymmetric semipermeable membrane for the treatment of biological fluids |
US5383925A (en) * | 1992-09-14 | 1995-01-24 | Meadox Medicals, Inc. | Three-dimensional braided soft tissue prosthesis |
US5468430A (en) * | 1994-05-19 | 1995-11-21 | L'air Liquide S.A. | Process of making multicomponent or asymmetric gas separation membranes |
US5472607A (en) * | 1993-12-20 | 1995-12-05 | Zenon Environmental Inc. | Hollow fiber semipermeable membrane of tubular braid |
US5863645A (en) * | 1994-01-17 | 1999-01-26 | Mitsubishi Rayon Co., Ltd. | Composite microporous polyolefin membrane and a method of producing the same |
US5868936A (en) * | 1996-06-20 | 1999-02-09 | Baxter International Inc. | Affinity membrane system and method of using same |
US5919370A (en) * | 1995-05-24 | 1999-07-06 | Akzo Nobel Nv | Integral, multi-asymmetric, semi-permeable membrane |
US6074718A (en) * | 1996-02-06 | 2000-06-13 | Koch Membrane Systems, Inc. | Self supporting hollow fiber membrane and method of construction |
US6146747A (en) * | 1997-01-22 | 2000-11-14 | Usf Filtration And Separations Group Inc. | Highly porous polyvinylidene difluoride membranes |
US6284137B1 (en) * | 1994-06-07 | 2001-09-04 | Mitsubishi Rayon Co., Ltd. | Polysulfone porous membrane and a method of manufacturing the same |
US6565782B1 (en) * | 1996-12-12 | 2003-05-20 | Pall Corporation | Highly asymmetric, hydrophilic, microfiltration membranes having large pore diameters |
US20040124135A1 (en) * | 2000-08-07 | 2004-07-01 | Richard Sale | Unsupported multizone microporous membrane |
US6809971B2 (en) * | 2000-02-02 | 2004-10-26 | Broadcom Corporation | Diffusion replica delay circuit method |
US6951811B2 (en) * | 2003-05-12 | 2005-10-04 | Shinko Electric Industries Co., Ltd. | Method of producing vias and other conductor parts on an electrode terminal forming surface of a semiconductor wafer |
US20050274665A1 (en) * | 2002-03-13 | 2005-12-15 | Klaus Heilmann | Capillary membrane and device for production thereof |
US7087168B2 (en) * | 2001-07-24 | 2006-08-08 | Asahi Kasei Medical Co., Ltd. | Hollow fiber membrane for purifying blood |
US7128861B2 (en) * | 2001-03-06 | 2006-10-31 | Asahi Kasei Chemicals Corporation | Method for producing hollow yarn film |
US7172075B1 (en) * | 2003-08-08 | 2007-02-06 | Accord Partner Limited | Defect free composite membranes, method for producing said membranes and use of the same |
US20070199891A1 (en) * | 2004-03-22 | 2007-08-30 | Kimihiro Mabuchi | Separation Membrane With Selective Permeability And Process For Producing The Same |
US7306754B2 (en) * | 2000-07-08 | 2007-12-11 | Universitat Twente | Membrane and the use thereof |
US20090216173A1 (en) * | 2004-05-12 | 2009-08-27 | Gensrich Juergen | Blood detoxification membrane, method for producing same, and use thereof |
US7632439B2 (en) * | 2002-02-12 | 2009-12-15 | Siemens Water Technologies Corp. | Poly(ethylene chlorotrifluoroethylene) membranes |
US7815987B2 (en) * | 2008-12-04 | 2010-10-19 | Dow Global Technologies Inc. | Polyamide membrane with coating of polyalkylene oxide and polyacrylamide compounds |
US7861869B2 (en) * | 2004-11-19 | 2011-01-04 | Vlaamse Instelling Voor Technologisch Onderzoek (Vito) | Reinforced capillary membranes and process for manufacturing thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58132112A (en) * | 1982-02-02 | 1983-08-06 | Nok Corp | Production of hollow fiber |
JPS6219205A (en) * | 1985-07-17 | 1987-01-28 | Nok Corp | Preparation of ultrafilter membrane |
JPS62102801A (en) * | 1985-10-28 | 1987-05-13 | Toray Ind Inc | Selective permeable hollow composite fiber |
JPH0693985B2 (en) * | 1988-12-23 | 1994-11-24 | 宇部興産株式会社 | Manufacturing method of polyimide two-layer hollow fiber membrane |
JP2728549B2 (en) * | 1990-07-04 | 1998-03-18 | 帝人株式会社 | Method for producing composite hollow fiber |
US5298206A (en) * | 1992-02-04 | 1994-03-29 | W. R. Grace & Co.-Conn. | Method and apparatus for casting hollow fiber membranes |
JP4265701B2 (en) * | 1998-11-16 | 2009-05-20 | 旭化成クラレメディカル株式会社 | Polysulfone porous membrane |
DE19907824A1 (en) * | 1999-02-24 | 2000-08-31 | Univ Twente Fakultaet Chemisch | Membrane and their use |
JP2001038171A (en) * | 1999-08-03 | 2001-02-13 | Toyobo Co Ltd | Hollow fiber membrane |
JP4626301B2 (en) * | 2002-06-14 | 2011-02-09 | 東レ株式会社 | Composite separation membrane and method for producing the same |
CN100503020C (en) * | 2002-09-12 | 2009-06-24 | 旭化成可乐丽医疗株式会社 | Plasma purifying membrane and plasma purifying system |
-
2007
- 2007-04-23 DE DE102007019051A patent/DE102007019051B3/en active Active
-
2008
- 2008-04-21 CN CN200880007551A patent/CN101626821A/en active Pending
- 2008-04-21 JP JP2010504519A patent/JP5010026B2/en active Active
- 2008-04-21 US US12/594,694 patent/US9149770B2/en active Active
- 2008-04-21 EP EP08749030.6A patent/EP2155368B1/en active Active
- 2008-04-21 WO PCT/EP2008/003195 patent/WO2008128749A1/en active Application Filing
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933085A (en) * | 1987-05-20 | 1990-06-12 | Gkss-Forschungszentrum Geesthacht Gmbh | Method of manufacturing an integral asymmetrical membrane |
US5141642A (en) * | 1987-10-09 | 1992-08-25 | Ube Industries, Ltd. | Aromatic polyimide double layered hollow filamentary membrane and process for producing same |
US5034129A (en) * | 1988-09-09 | 1991-07-23 | Stork Friesland B.V. | Membrane assembly |
US5145583A (en) * | 1989-12-22 | 1992-09-08 | Hospal Industrie | Asymmetric semipermeable membrane for the treatment of biological fluids |
US5383925A (en) * | 1992-09-14 | 1995-01-24 | Meadox Medicals, Inc. | Three-dimensional braided soft tissue prosthesis |
US5472607A (en) * | 1993-12-20 | 1995-12-05 | Zenon Environmental Inc. | Hollow fiber semipermeable membrane of tubular braid |
US5863645A (en) * | 1994-01-17 | 1999-01-26 | Mitsubishi Rayon Co., Ltd. | Composite microporous polyolefin membrane and a method of producing the same |
US5468430A (en) * | 1994-05-19 | 1995-11-21 | L'air Liquide S.A. | Process of making multicomponent or asymmetric gas separation membranes |
US6284137B1 (en) * | 1994-06-07 | 2001-09-04 | Mitsubishi Rayon Co., Ltd. | Polysulfone porous membrane and a method of manufacturing the same |
US5919370A (en) * | 1995-05-24 | 1999-07-06 | Akzo Nobel Nv | Integral, multi-asymmetric, semi-permeable membrane |
US6074718A (en) * | 1996-02-06 | 2000-06-13 | Koch Membrane Systems, Inc. | Self supporting hollow fiber membrane and method of construction |
US5868936A (en) * | 1996-06-20 | 1999-02-09 | Baxter International Inc. | Affinity membrane system and method of using same |
US5871649A (en) * | 1996-06-20 | 1999-02-16 | Baxter International Inc. | Affinity membrane system and method of using same |
US6565782B1 (en) * | 1996-12-12 | 2003-05-20 | Pall Corporation | Highly asymmetric, hydrophilic, microfiltration membranes having large pore diameters |
US6146747A (en) * | 1997-01-22 | 2000-11-14 | Usf Filtration And Separations Group Inc. | Highly porous polyvinylidene difluoride membranes |
US6809971B2 (en) * | 2000-02-02 | 2004-10-26 | Broadcom Corporation | Diffusion replica delay circuit method |
US7306754B2 (en) * | 2000-07-08 | 2007-12-11 | Universitat Twente | Membrane and the use thereof |
US20040124135A1 (en) * | 2000-08-07 | 2004-07-01 | Richard Sale | Unsupported multizone microporous membrane |
US7128861B2 (en) * | 2001-03-06 | 2006-10-31 | Asahi Kasei Chemicals Corporation | Method for producing hollow yarn film |
US7087168B2 (en) * | 2001-07-24 | 2006-08-08 | Asahi Kasei Medical Co., Ltd. | Hollow fiber membrane for purifying blood |
US7632439B2 (en) * | 2002-02-12 | 2009-12-15 | Siemens Water Technologies Corp. | Poly(ethylene chlorotrifluoroethylene) membranes |
US20050274665A1 (en) * | 2002-03-13 | 2005-12-15 | Klaus Heilmann | Capillary membrane and device for production thereof |
US6951811B2 (en) * | 2003-05-12 | 2005-10-04 | Shinko Electric Industries Co., Ltd. | Method of producing vias and other conductor parts on an electrode terminal forming surface of a semiconductor wafer |
US7172075B1 (en) * | 2003-08-08 | 2007-02-06 | Accord Partner Limited | Defect free composite membranes, method for producing said membranes and use of the same |
US20070199891A1 (en) * | 2004-03-22 | 2007-08-30 | Kimihiro Mabuchi | Separation Membrane With Selective Permeability And Process For Producing The Same |
US20090216173A1 (en) * | 2004-05-12 | 2009-08-27 | Gensrich Juergen | Blood detoxification membrane, method for producing same, and use thereof |
US7861869B2 (en) * | 2004-11-19 | 2011-01-04 | Vlaamse Instelling Voor Technologisch Onderzoek (Vito) | Reinforced capillary membranes and process for manufacturing thereof |
US7815987B2 (en) * | 2008-12-04 | 2010-10-19 | Dow Global Technologies Inc. | Polyamide membrane with coating of polyalkylene oxide and polyacrylamide compounds |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110263020A1 (en) * | 2008-09-25 | 2011-10-27 | Gambro Lundia Ab | Membrane for cell expansion |
US20120067815A1 (en) * | 2008-09-25 | 2012-03-22 | Gambro Lundia Ab | Hybrid bioartificial kidney |
US8435751B2 (en) * | 2008-09-25 | 2013-05-07 | Gambro Lundia Ab | Membrane for cell expansion |
US8696909B2 (en) * | 2008-09-25 | 2014-04-15 | Gambro Lundia Ab | Hybrid bioartificial kidney |
US20110266223A1 (en) * | 2008-10-15 | 2011-11-03 | National University Of Singapore | Dual-layer hollow fibers with enhanced flux as forward osmosis membranes for water reuses and protein enrichment |
US20140284267A1 (en) * | 2011-10-04 | 2014-09-25 | Mn Beteiligungs Gmbh | Abrasion-proof filtration membrane and method of producing said membrane |
US10478785B2 (en) * | 2011-10-04 | 2019-11-19 | Mn Beteiligungs Gmbh | Abrasion-proof filtration membrane and method of producing said membrane |
US10822461B2 (en) | 2017-10-05 | 2020-11-03 | Fresenius Medical Care Holdings, Inc. | Polysulfone-urethane copolymer, membranes and products incorporating same, and methods for making and using same |
US11499016B2 (en) | 2017-10-05 | 2022-11-15 | Fresenius Medical Care Holdings, Inc. | Polysulfone-urethane copolymer, membranes and products incorporating same, and methods for making and using same |
Also Published As
Publication number | Publication date |
---|---|
JP2010525932A (en) | 2010-07-29 |
US20100163488A1 (en) | 2010-07-01 |
EP2155368A1 (en) | 2010-02-24 |
US9149770B2 (en) | 2015-10-06 |
CN101626821A (en) | 2010-01-13 |
DE102007019051B3 (en) | 2008-10-09 |
WO2008128749A1 (en) | 2008-10-30 |
EP2155368B1 (en) | 2019-06-05 |
JP5010026B2 (en) | 2012-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9149770B2 (en) | Hollow fiber capillary membrane and method for the production thereof | |
KR101295949B1 (en) | Plasma separation membrane | |
US5232601A (en) | High flux hollow fiber membrane | |
CN110290858B (en) | Hollow fiber membrane with improved separation efficiency and manufacture of hollow fiber membrane with improved separation efficiency | |
KR101413935B1 (en) | Hollow fiber membrane and method for manufacturing thereof | |
US7931154B2 (en) | Plasma separation membrane | |
US10188991B2 (en) | Permselective asymmetric membranes | |
DE102008003090A1 (en) | Hollow fiber membrane | |
EP0842694A1 (en) | Hollow yarn membrane used for blood purification and blood purifier | |
JP5440332B2 (en) | Hollow fiber membrane | |
US10888823B2 (en) | Membrane with improved permeability and selectivity | |
CN112203749A (en) | Membrane for capillary microfiltration | |
JP2792556B2 (en) | Blood purification module, blood purification membrane and method for producing the same | |
Krause et al. | Polymeric membranes for medical applications | |
JP5212837B2 (en) | Permselective hollow fiber membrane | |
JPH09308685A (en) | Hollow fiber membrane for blood purification and blood purifying device | |
CN113316481A (en) | Dialyzer comprising fluorine-containing hollow fiber membranes | |
JP6030295B2 (en) | Blood purifier manufacturing method | |
JP2023529298A (en) | Hollow fiber membrane for separating plasma from blood | |
JP2005342415A (en) | High water-permeable hollow-fiber membrane-type blood purification apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH,GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FISLAGE, RAINER;HEILMANN, KLAUS;KELLER, TORSTEN;AND OTHERS;SIGNING DATES FROM 20090904 TO 20090912;REEL/FRAME:024223/0232 Owner name: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FISLAGE, RAINER;HEILMANN, KLAUS;KELLER, TORSTEN;AND OTHERS;SIGNING DATES FROM 20090904 TO 20090912;REEL/FRAME:024223/0232 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |